Back

Latest Forum Topics / QT Vascular

Post Reply

QT Vascular Going BIG Post Reply Rate topic
dingbat Veteran	13-May-2014 17:14        dingbat About Contact  Quote this Post!
x 0   x 0  Alert Admin	Dun mind me asking where you got this TP..... Breeze      ( Date: 13-May-2014 17:05) Posted: Est. 40-42 target price. gd luck
Useful To Me  Not Useful To Me
Breeze Member	13-May-2014 17:05        Breeze About Contact  Quote this Post!
x 0   x 0  Alert Admin	Est. 40-42 target price. gd luck
Useful To Me  Not Useful To Me
cleverboy Member	08-May-2014 16:43        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	the company web site is www.qtvascular.com. useful info there to know about the company and its products.
Useful To Me  Not Useful To Me
RoundRound Elite	07-May-2014 09:25        RoundRound About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Tikam Tikam can also"
x 0   x 0  Alert Admin	This stock must have taken steroid. Up 20% in 3 trading days
Useful To Me  Not Useful To Me
cleverboy Member	06-May-2014 23:12        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Happy to share info.  Good that you highlights those points, which I believe that there are others who feel similarly.  Investment is also a learning process.  Stay hungry Stay foolish.
Useful To Me  Not Useful To Me
sheerluck Supreme	06-May-2014 22:47        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	for your conviction on this coy.   You seems to know quite abit about all this medical stuff and have done quite a bit of research on this coy being the only one who bothers to answer all my doubts although they still remains as my doubts. Hope QT future results provides more clarity for me.   I don' t spent all this time questioning it because I don' t like it.   On the contrary, this is a interesting coy to me but I viewed it highly risky to take on any position with it atm. In the meantime enjoy huating!    cleverboy      ( Date: 06-May-2014 22:15) Posted: How much does one tablet of paracetamol cost?  Probably 10 or 20 cents.  How many do you take each time?  For adults, 2 tablets (500mg each) each time.  Did your doctor tell you that you have to take it at least 4 hours apart and not to take more than 8 tables (400mg) in a 24-hour period? Do you know that paracetamol can cause liver damage?  And what is the margin in manufacturing paracetamol, a product that was first launched in USA in 1950 and the patent on which has long expired?  I don' t know.  My guess is that the margin is very very low and you need to produce in millions or may be billions in order to reach the economy of scale to ensure a decent absolute profit.  And if you are suffering from a pain that 2 tablets of paracetamol can alleviate, I guess you would probably survive without taking it and just have a good sleep instead. When one suffers from Peripheral vascular disease (definition can be found below), do you treat it if you have an option to treat? Or do you go and take a sleep just like the case when one choose not to take a paracetamol?  When the arteries to your legs, arms, stomach and kidneys are blocked by plague, and it costs you a lot more than paracetamol, would you treat it?  Tell me that you are poor and that you cannot afford to be treated is a separate issue.  If you have medishield or any form of medical insurance, would you treat it?  I think most people will say yes as PV disease is a serious disease that can lead to complication such as amputation of limbs, kidney failure and even death if left untreated.  So it is not about paracetamol please. Extract from prospectus on the industry about PAD Peripheral vascular disease (&ldquo PV disease&rdquo ) refers to diseases of the blood vessels outside the heart and brain, and commonly occurs in the legs, arms, stomach and kidneys. Peripheral Artery Disease (&ldquo PAD&rdquo ) is a type of PV disease caused by the build-up of plaque in the arteries. The treatments available to PAD are similar, if not identical, to other types of PV diseases and often a successful treatment in one type of PV disease will lead to trials of that treatment method in other types of PV diseases. The market size for peripheral vascular devices (&ldquo PV devices&rdquo ) is estimated to reach US$7.8 billion by 2018, having grown at a compound annual growth rate (&ldquo CAGR&rdquo ) of 7.1% from US$4.8 billion in 2011. In the US, the PV devices market is estimated to be worth US$2.6 billion, with theexpectation of a 5% CAGR through 2017. In Europe, the PV devices market is currently worth US$1.2 billion and is expected to grow at a similar 5% CAGR through 2017. The PV devices market in Japan is expected to grow more slowly at 1% CAGR from US$0.5 billion in 2012. China is expected to be one of the fastest growing markets (in 2011 the Chinese PV market was valued at over US$287 million) due to the rise in the ageing population and the ongoing investment in healthcare. PAD is estimated to affect 202 million people(1) worldwide. This disease reduces blood flow to the lower extremities and in severe cases a complete loss of blood flow to the limb, leading to amputation of the limb. This disease is most prevalent in the over 65 year old population, and with the increasing life expectancy in developed countries, the number of cases of PAD is expected to increase. Due to the nature of the disease, it is estimated that at least 50% of the people suffering from PAD are currently undiagnosed. With the expansion of healthcare services in many countries and the recovery of the economic environment, it is expected that more people will be diagnosed and treated for PAD. Many cases of PAD are treated using minimally invasive procedures, such as Percutaneous Transluminal Angioplasty (&ldquo PTA&rdquo ) balloon catheters. These devices have gone through many improvements over the last few decades, improving their efficacy and reducing their costs. New and novel devices are still coming to market, for example the IN.PACT drug coated balloon from Medtronic, Inc. (&ldquo Medtronic&rdquo ) and the Lutonix Inc (&ldquo Lutonix&rdquo ) drug coated balloon from C.R. Bard, Inc. (&ldquo CR Bard&rdquo ). Both the IN.PACT drug coated balloon from Medtronic and the Lutonix drug coated balloon from CR Bard are available for sale in Europe and are completing trials in the US with market launch in US expected to be in the 2015 to 2016 timeframe. These new devices are expected to still be able to command a high average selling price (&ldquo ASP&rdquo ) through their increased efficacy and ease-of-use. The rapid increase in the size of the ageing population, along with increasing awareness of the disease are the main drivers behind the increase in number of procedures (see Figure 1). With the recent economic downtown, many governments across the world are looking to reduce healthcare costs. As the majority of the healthcare systems are government funded there is an increased pressure on hospitals to drive down the ASPs of existing devices or reduce the number of devices used. However, new devices with better efficacy are maintaining their ASPs overall due to their ability to deliver better clinical results and reduce complications, leading to better patient outcomes. The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US with expected launch dates in the 2014 to 2016 timeframe. Factually, QTV' s products are never meant to be a mass market product like paracetamol or antibiotics.  QTV' s products are meant for a targeted group of patients who suffer from serious illness and who would most likely prefer to be treated and stay living longer rather than be untreated and die earlier.  QTV' s products are meant for the world markets.  QTV' s products are not meant to be dispensed off 7-eleven' s shelf, those of which command meagre margins.  Yes QTV is facing competition from existing big players, which it acknowledges and thus counteract by working with existing big players such as Johnson & Johnson, Weigao, Century Medical as its stragetic distributors to gain market share and enhance its sales. Happy to share more factual and complete information.   sheerluck      ( Date: 06-May-2014 21:05) Posted: Good effort on the coy to maintain investors confident.   Surely if they don' t bring their products into Singapore having listed here and gotten lcoal investors money, it is bad publicity. But I still have doubts.   Really we are talking about specialised product that requires surgery procedure.   It not like  paracetamol that you can buy of the shelf and administrate it yourself.   You may buy  paracetamol more than once in a year and almost anyone can buy it but you really cannot expect the same from these products. Sure there are 202 miliion PAD cases but this ballon thing is one of the possible treatment not the only one and I don' think these product and the surgery are themselve cheap.   Right? They are also competing with some big players: The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US with expected launch dates in the 2014 to 2016 timeframe. So back to my inital doubts about its prospect that it is not a mass-market product, it needs surgery procedure, it faces fierce competion from existing big players.   These big boys should have their own established distribution channels so their cost may be a lot lower than QT' s.   If they slash margin (if they can afford to) to gain market share, can QT survive?   Will QT revenue not be volatile? Sure, one day it may get acquire by another company, one which wants a pie of the action. Apologise first as I really don' t mean to dampen it as it had such a nice run-up today. Any counter-arguements welcome! DYDD.   Correction:   Dr Eitan. owns those share at 0.02cts not 2cts.   Sure, this coy is his baby so he may not dump.
Useful To Me  Not Useful To Me
cleverboy Member	06-May-2014 22:15        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	How much does one tablet of paracetamol cost?  Probably 10 or 20 cents.  How many do you take each time?  For adults, 2 tablets (500mg each) each time.  Did your doctor tell you that you have to take it at least 4 hours apart and not to take more than 8 tables (400mg) in a 24-hour period? Do you know that paracetamol can cause liver damage?  And what is the margin in manufacturing paracetamol, a product that was first launched in USA in 1950 and the patent on which has long expired?  I don' t know.  My guess is that the margin is very very low and you need to produce in millions or may be billions in order to reach the economy of scale to ensure a decent absolute profit.  And if you are suffering from a pain that 2 tablets of paracetamol can alleviate, I guess you would probably survive without taking it and just have a good sleep instead. When one suffers from Peripheral vascular disease (definition can be found below), do you treat it if you have an option to treat? Or do you go and take a sleep just like the case when one choose not to take a paracetamol?  When the arteries to your legs, arms, stomach and kidneys are blocked by plague, and it costs you a lot more than paracetamol, would you treat it?  Tell me that you are poor and that you cannot afford to be treated is a separate issue.  If you have medishield or any form of medical insurance, would you treat it?  I think most people will say yes as PV disease is a serious disease that can lead to complication such as amputation of limbs, kidney failure and even death if left untreated.  So it is not about paracetamol please. Extract from prospectus on the industry about PAD Peripheral vascular disease (&ldquo PV disease&rdquo ) refers to diseases of the blood vessels outside the heart and brain, and commonly occurs in the legs, arms, stomach and kidneys. Peripheral Artery Disease (&ldquo PAD&rdquo ) is a type of PV disease caused by the build-up of plaque in the arteries. The treatments available to PAD are similar, if not identical, to other types of PV diseases and often a successful treatment in one type of PV disease will lead to trials of that treatment method in other types of PV diseases. The market size for peripheral vascular devices (&ldquo PV devices&rdquo ) is estimated to reach US$7.8 billion by 2018, having grown at a compound annual growth rate (&ldquo CAGR&rdquo ) of 7.1% from US$4.8 billion in 2011. In the US, the PV devices market is estimated to be worth US$2.6 billion, with theexpectation of a 5% CAGR through 2017. In Europe, the PV devices market is currently worth US$1.2 billion and is expected to grow at a similar 5% CAGR through 2017. The PV devices market in Japan is expected to grow more slowly at 1% CAGR from US$0.5 billion in 2012. China is expected to be one of the fastest growing markets (in 2011 the Chinese PV market was valued at over US$287 million) due to the rise in the ageing population and the ongoing investment in healthcare. PAD is estimated to affect 202 million people(1) worldwide. This disease reduces blood flow to the lower extremities and in severe cases a complete loss of blood flow to the limb, leading to amputation of the limb. This disease is most prevalent in the over 65 year old population, and with the increasing life expectancy in developed countries, the number of cases of PAD is expected to increase. Due to the nature of the disease, it is estimated that at least 50% of the people suffering from PAD are currently undiagnosed. With the expansion of healthcare services in many countries and the recovery of the economic environment, it is expected that more people will be diagnosed and treated for PAD. Many cases of PAD are treated using minimally invasive procedures, such as Percutaneous Transluminal Angioplasty (&ldquo PTA&rdquo ) balloon catheters. These devices have gone through many improvements over the last few decades, improving their efficacy and reducing their costs. New and novel devices are still coming to market, for example the IN.PACT drug coated balloon from Medtronic, Inc. (&ldquo Medtronic&rdquo ) and the Lutonix Inc (&ldquo Lutonix&rdquo ) drug coated balloon from C.R. Bard, Inc. (&ldquo CR Bard&rdquo ). Both the IN.PACT drug coated balloon from Medtronic and the Lutonix drug coated balloon from CR Bard are available for sale in Europe and are completing trials in the US with market launch in US expected to be in the 2015 to 2016 timeframe. These new devices are expected to still be able to command a high average selling price (&ldquo ASP&rdquo ) through their increased efficacy and ease-of-use. The rapid increase in the size of the ageing population, along with increasing awareness of the disease are the main drivers behind the increase in number of procedures (see Figure 1). With the recent economic downtown, many governments across the world are looking to reduce healthcare costs. As the majority of the healthcare systems are government funded there is an increased pressure on hospitals to drive down the ASPs of existing devices or reduce the number of devices used. However, new devices with better efficacy are maintaining their ASPs overall due to their ability to deliver better clinical results and reduce complications, leading to better patient outcomes. The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US with expected launch dates in the 2014 to 2016 timeframe. Factually, QTV' s products are never meant to be a mass market product like paracetamol or antibiotics.  QTV' s products are meant for a targeted group of patients who suffer from serious illness and who would most likely prefer to be treated and stay living longer rather than be untreated and die earlier.  QTV' s products are meant for the world markets.  QTV' s products are not meant to be dispensed off 7-eleven' s shelf, those of which command meagre margins.  Yes QTV is facing competition from existing big players, which it acknowledges and thus counteract by working with existing big players such as Johnson & Johnson, Weigao, Century Medical as its stragetic distributors to gain market share and enhance its sales. Happy to share more factual and complete information.   sheerluck      ( Date: 06-May-2014 21:05) Posted: Good effort on the coy to maintain investors confident.   Surely if they don' t bring their products into Singapore having listed here and gotten lcoal investors money, it is bad publicity. But I still have doubts.   Really we are talking about specialised product that requires surgery procedure.   It not like  paracetamol that you can buy of the shelf and administrate it yourself.   You may buy  paracetamol more than once in a year and almost anyone can buy it but you really cannot expect the same from these products. Sure there are 202 miliion PAD cases but this ballon thing is one of the possible treatment not the only one and I don' think these product and the surgery are themselve cheap.   Right? They are also competing with some big players: The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US with expected launch dates in the 2014 to 2016 timeframe. So back to my inital doubts about its prospect that it is not a mass-market product, it needs surgery procedure, it faces fierce competion from existing big players.   These big boys should have their own established distribution channels so their cost may be a lot lower than QT' s.   If they slash margin (if they can afford to) to gain market share, can QT survive?   Will QT revenue not be volatile? Sure, one day it may get acquire by another company, one which wants a pie of the action. Apologise first as I really don' t mean to dampen it as it had such a nice run-up today. Any counter-arguements welcome! DYDD.   Correction:   Dr Eitan. owns those share at 0.02cts not 2cts.   Sure, this coy is his baby so he may not dump.
Useful To Me  Not Useful To Me
sheerluck Supreme	06-May-2014 21:05        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	Good effort on the coy to maintain investors confident.   Surely if they don' t bring their products into Singapore having listed here and gotten lcoal investors money, it is bad publicity. But I still have doubts.   Really we are talking about specialised product that requires surgery procedure.   It not like  paracetamol that you can buy of the shelf and administrate it yourself.   You may buy  paracetamol more than once in a year and almost anyone can buy it but you really cannot expect the same from these products. Sure there are 202 miliion PAD cases but this ballon thing is one of the possible treatment not the only one and I don' think these product and the surgery are themselve cheap.   Right? They are also competing with some big players: The market leaders in the treatment of PAD include large medical companies such as Boston Scientific Corporation (&ldquo Boston Scientific&rdquo ), Johnson & Johnson, Covidien Ltd. (&ldquo Covidien&rdquo ), CR Bard, and Abbott Laboratories. Often, they have carved out a niche in a particular part of the peripheral vascular market (&ldquo PV market&rdquo ). However, as instances and awareness of PAD increase, more and more companies are looking to gain entry into the market, leading to ever shifting market shares, ongoing price pressure and the development of new devices as the companies strive to differentiate their offerings. These large incumbents often grow by acquiring smaller companies in the market for their new and upcoming devices, for example CR Bard acquired Lutonix in 2011 for its drug-coated balloons (&ldquo DCB&rdquo ) device and Covidien acquired CV Ingenuity Corp. for its DCB in 2012. These acquired devices are often still completing clinical trials at the point of acquisition. This is especially true of the new drug-eluting balloons (&ldquo DEB&rdquo ) and DCB devices, the majority of which have CE Marks and are going through clinical trials in the US with expected launch dates in the 2014 to 2016 timeframe. So back to my inital doubts about its prospect that it is not a mass-market product, it needs surgery procedure, it faces fierce competion from existing big players.   These big boys should have their own established distribution channels so their cost may be a lot lower than QT' s.   If they slash margin (if they can afford to) to gain market share, can QT survive?   Will QT revenue not be volatile? Sure, one day it may get acquire by another company, one which wants a pie of the action. Apologise first as I really don' t mean to dampen it as it had such a nice run-up today. Any counter-arguements welcome! DYDD.   Correction:   Dr Eitan. owns those share at 0.02cts not 2cts.   Sure, this coy is his baby so he may not dump.
Useful To Me  Not Useful To Me
cleverboy Member	06-May-2014 19:45        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Press release by QT Vascular Ltd - QT Vascular initiates Chocolate Cases in Singapore Chocolate® PTA may benefit Singaporean patients suffering from peripheral arterial disease SINGAPORE, May 6, 2014 /PRNewswire/ -- QT Vascular Ltd. (QT Vascular) is pleased to announce that it has started clinical cases with the Chocolate® PTA balloon catheter (Chocolate® PTA) in Singapore. Five cases were performed at National University Hospital (NUH) and Changi General Hospital (CGH). Speaking after the procedures, Dr. Steven Kum, a vascular surgeon at CGH and an expert in treating peripheral arterial disease (PAD), stated, &ldquo After treating several patients with severe disease both above and below the knee, I believe that Chocolate PTA has an important role in the peripheral lab as it offers less traumatic treatment without the use of a permanent implant. I' m also very excited about the potential for the Drug-Coated Chocolate balloon for below the knee disease that is more common in Singapore because there are no adequate treatment options for those patients.&rdquo Added Dr. Julian Wong, Division head, Vascular & Endovascular Surgery at NUH, &ldquo I truly agree with Dr. Kum. Chocolate PTA gives a more uniform angioplasty result with less intimal dissection. It has a great potential in reducing the use of stents in complex lesions below and above the knee.&rdquo According to Singapore Health Services, PAD is a major cause of limb loss (amputation) in Singapore.  However, it does not receive as much attention as diseases involving the other vascular beds, namely coronary artery disease and cerebrovascular disease (1). The Chocolate® PTA design represents a breakthrough in PTA balloon catheters. The Chocolate® PTA is used for the treatment of patients with vascular disease in their legs, known as PAD. It was designed to provide predictable, uniform, less traumatic dilatation of peripheral vasculature. The Chocolate® PTA has demonstrated a very low rate of dissections and bail-out stenting in clinical studies in the United States(2). QT Vascular&rsquo s product pipeline includes a Drug-Coated Chocolate balloon. It combines the acute benefits of the Chocolate® PTA with paclitaxel-based coating, an anti-proliferative drug that has been shown to be efficacious in the prevention of re-narrowing of the artery over time. &ldquo The cases performed at these prestigious institutions mark a key milestone in QT Vascular&rsquo s journey to bring improved PAD treatment options to patients&rdquo , said Dr. Eitan Konstantino, Chief Executive Officer of QT Vascular, &ldquo We are very excited to treat patients in Singapore, our home base.&rdquo About Peripheral Arterial Disease Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide (3). About QT Vascular QT Vascular Ltd. (QTV) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QTV is based in Singapore with a US subsidiary, TriReme Medical, in Pleasanton, California. The Company was listed on the Catalist of the Singapore Exchange Securities Trading Limited on 29 April 2014. References: (1) Singapore Health Services website (http://www.singhealth.com.sg/PatientCare/ConditionsAndTreatments/Pages/Peripheral-Arterial-Disease.aspx). (2) Das T for Mustapha J. Chocolate® Bar, Leipzig Interventional Course, 28-31 January, 2014. (3) " Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis." 19 Oct 2013. The Lancet.
Useful To Me  Not Useful To Me
cleverboy Member	06-May-2014 10:23        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	To complete the fact about J& J investment in QTV for all to know.  Apart from the pre-IPO investment of US$2.5mil at 20% discount, J& J' s subscription to the IPO of about S$3mil seems to equal to another US$2.5 mil investment at IPO.  So on average, J& J invest about US$5mil at 10% discount.  10% return for a risky investment seems low to me.  So may be J& J doesn' t think it is that risky but rather important to have a stake in a company that may have a game changer technology and product. A meeting with the management of the company would do good for one to understand more.  Dr Eitan' s stake in the company is at a cheap price simply because he is the founder of the company.  Having his stake at a cheap cost does not necessarily mean he will sell at the first opportunity when available, but still we can rule that out.  However, I believe the commercial potential of its products if successful and the resulting enterprise value is a big enough carrot for the management to hold out their stake for a while longer.    How big can this carrot be?  I don' t know but I append a web link to a press release by CR Bard, who bought over Lutonix for US$325 mil in 2012 to establish a lead in the race of Drug Coated Ballon.  In the article, CR Bard stated " Bard anticipates the global peripheral vascular market alone for drug-coated balloons could approach $1 billion annually over the next 10 years. The firm estimates $100 million in Moxy sales for its first year on the U.S. market."     When Lutonix (which solely focus on drug eluting ballon) was sold to CR Bard, it had NO FDA approval, no sales but it has CE mark and First-In-Man trial. http://www.wsgr.com/news/medicaldevice/pdf/bard.pdf Cheers
Useful To Me  Not Useful To Me
sheerluck Supreme	05-May-2014 18:14        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	Excellent point on the thin margin issue cleverboy!   At least someone bother to look deeper.   Hope more people share their discoveries.   It definitely helps in adding more facts for one' s consideration. J& J did put in $$$$ but if you see page A-69, On 10 January 2014, the Company issued a convertible promissory note to Johnson & Johnson Development Corporation for a total gross proceed of $2,500,000. The note bears an interest rate of 8% per annum. Upon an IPO, the principal amount of the note and accrued interest, if any, will be convertible into ordinary shares of the Company at a 20% discount from the IPO price. If the IPO is completed within 12 months from the date of agreement, no interest is payable in respect of the principal amount. No interest will be due if the note is converted into ordinary shares within one year from the date of agreement. 8% interest or a 20% discount to IPO price should say something about how J& J is squeezing QT even for the small investment it is doing or another view how risky QT is that J& J wants such a premium.   Either way J& J wouldn' t lose out. Beside those pre-IPO investors, Dr Eitan has 13millions share at 2cts.   Another one to watch out. Anyway, I hope this is QT year and they turn around strongly to contribute to SG economy and more importantly retail investors' pocket who had placed their trust in them. Disclaimer:   not trying to shoot down QT.  Anyway, it is a preminarily a timing issues: To take the plunge  now or wait till the wave subside to have a clearer view.   DYDD.  Happy huating!   cleverboy      ( Date: 05-May-2014 17:19) Posted: sheerluck is right to point out that it is not EDB mandate to ensure that the company is profitable.  However, I think EDB hopes to make money out of its investment and at the same time attract more bio-tech company to set up office here.  Profitability is always one of the objectives of the company.  On the point about whether the company is doing an IPO when they are faring their worse, I can' t fully comprehend as I look at the milestone the company has achieved so far.  Two years before the IPO, there was no regulatory approval, no distribution partners and no acceptance of the products.  At IPO time, its has regulatory approval, some market acceptance, good distribution partner and ongoing product pipeline.  So rightuflly to speak that it is at its worst, I presume sheerluck is talking about finacial results. Looking through the prospectus, I wasn' t able to agree with the point on " already thin margin" .  The co' s sales revenue that have been reported so far have been small especially in the context of the world' s largest market for stents ie USA.  I guess the company' s current sales volume has not reached the breakeven point, which is quite typical of any company ramping up its sales.  How far or how close is the sales from its breakeven point is important as the nearer it is, the quicker the company would turn profitable.  In addition to distributing the products, J& J actually invested about US$5 mil into the company, through pre-IPO (US$2.5mil) and IPO (S$3 mil).  Yes, I agree with sheerluck that I don' t think J& J is just distributing their products.  It have to be that J& J believes the commercial potential of the products.  To bring a product into J& J' s catalogue, it requries huge investment in terms of training of sales people, conduct of seminars to educate and promote the products to hospitals and doctors, print of marketing and advertising materials, stock up of inventories and product liability insurance.  And we are not talking about just one USA markets but world markets that cover many countries.  As for pre-IPO investors, lets hope that they continue to ride their profit long and cut their other losses short, which is a better way to investment.
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 17:19        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	sheerluck is right to point out that it is not EDB mandate to ensure that the company is profitable.  However, I think EDB hopes to make money out of its investment and at the same time attract more bio-tech company to set up office here.  Profitability is always one of the objectives of the company.  On the point about whether the company is doing an IPO when they are faring their worse, I can' t fully comprehend as I look at the milestone the company has achieved so far.  Two years before the IPO, there was no regulatory approval, no distribution partners and no acceptance of the products.  At IPO time, its has regulatory approval, some market acceptance, good distribution partner and ongoing product pipeline.  So rightuflly to speak that it is at its worst, I presume sheerluck is talking about finacial results. Looking through the prospectus, I wasn' t able to agree with the point on " already thin margin" .  The co' s sales revenue that have been reported so far have been small especially in the context of the world' s largest market for stents ie USA.  I guess the company' s current sales volume has not reached the breakeven point, which is quite typical of any company ramping up its sales.  How far or how close is the sales from its breakeven point is important as the nearer it is, the quicker the company would turn profitable.  In addition to distributing the products, J& J actually invested about US$5 mil into the company, through pre-IPO (US$2.5mil) and IPO (S$3 mil).  Yes, I agree with sheerluck that I don' t think J& J is just distributing their products.  It have to be that J& J believes the commercial potential of the products.  To bring a product into J& J' s catalogue, it requries huge investment in terms of training of sales people, conduct of seminars to educate and promote the products to hospitals and doctors, print of marketing and advertising materials, stock up of inventories and product liability insurance.  And we are not talking about just one USA markets but world markets that cover many countries.  As for pre-IPO investors, lets hope that they continue to ride their profit long and cut their other losses short, which is a better way to investment.
Useful To Me  Not Useful To Me
spamalot Member	05-May-2014 16:35        spamalot About Contact  Quote this Post!
x 0   x 0  Alert Admin	Wow, bro cleverboy-- after your posts, this coy immediately rallied. Good job pushing the gem.
Useful To Me  Not Useful To Me
sheerluck Supreme	05-May-2014 16:28        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	Wow!   Someone just manged to grab 5millon share at 29cts under the table while others are trading way above it.   Something brewing????? sheerluck      ( Date: 05-May-2014 16:15) Posted: Great! At least someone bothered to read the prospectus. Firstly, I am surprised that EDB actually has an investment arm.   I really " suagu" .   But even so, I still discount that.   SG want to attract more bio-science coy to set up their high-end work in SG so QT may just fit into their criteria to fulfil someone portfolio maybe.   But I doubt it is EDB mandate to ensure that they are profitable.   Of course hopefully they are. They have new fund injected every year.   However, at the point where they are really faring their worse, they decided to sell to the public.   My take is that they may have (and I emphaise may have) potential to go big but they are pretty risky now that no new fund or existing fund wants to increase their stake anymore. The distribution with J& J Cordis may be a right step towards selling their products to the wider medical industry but  J& J Cordis wouldn' t do it for free.   What is their cut?   Hopefully it means Cordis can fetch a higher selling price to cover their take and not a further squeeze on the already thin margin.   Also I don' t think  J& J Cordis is just distributing their products.   To them, is what sell that matters.   If QT products sell, good.   If it does not, they might just focus their power on others that do.  We should also watch carefully the actions of those pre-IPO investors.   They are sitting on a huge profit now.   If QT does take off, they might hold on and everybody eats their cake.   If they don' t, there is nothing to prevent the pre-IPO from dumping and the fund may not want to further increase their stake. Still this coy might explode tomorrow for all I know.   If they showed creditable ans sustainable sale reveune, I might just be convinced.   until then, I stay at the sideline. DYDD.
Useful To Me  Not Useful To Me
sheerluck Supreme	05-May-2014 16:15        sheerluck About Contact  Quote this Post! Style: Flexible   Mood: Yells: "Work for your money first then let your money work for you"
x 0   x 0  Alert Admin	Great! At least someone bothered to read the prospectus. Firstly, I am surprised that EDB actually has an investment arm.   I really " suagu" .   But even so, I still discount that.   SG want to attract more bio-science coy to set up their high-end work in SG so QT may just fit into their criteria to fulfil someone portfolio maybe.   But I doubt it is EDB mandate to ensure that they are profitable.   Of course hopefully they are. They have new fund injected every year.   However, at the point where they are really faring their worse, they decided to sell to the public.   My take is that they may have (and I emphaise may have) potential to go big but they are pretty risky now that no new fund or existing fund wants to increase their stake anymore. The distribution with J& J Cordis may be a right step towards selling their products to the wider medical industry but  J& J Cordis wouldn' t do it for free.   What is their cut?   Hopefully it means Cordis can fetch a higher selling price to cover their take and not a further squeeze on the already thin margin.   Also I don' t think  J& J Cordis is just distributing their products.   To them, is what sell that matters.   If QT products sell, good.   If it does not, they might just focus their power on others that do.  We should also watch carefully the actions of those pre-IPO investors.   They are sitting on a huge profit now.   If QT does take off, they might hold on and everybody eats their cake.   If they don' t, there is nothing to prevent the pre-IPO from dumping and the fund may not want to further increase their stake. Still this coy might explode tomorrow for all I know.   If they showed creditable ans sustainable sale reveune, I might just be convinced.   until then, I stay at the sideline. DYDD.
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 14:38        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 14:31        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Part 3 pls refer to page 141 of the prospectus for the table that show procedural success and clinical outcomes. The company' s various products have received CE mark (Europe), FDA approvals (USA), Shonin approvals (Japan) and CFDA (China), while those in the pipelines are either being developed or pending approvals.  While these approvals do not speak of the commercial viability of the products, they mean the company have developed products that met regulatory requirements and are ready for commercial sales.  The various distributorship agreements that the company is able to secure from the major international premier distributors signal that these distributors are of the view that there are good commercial potentials for these products. In biomedical industry, the company with a potentially game changing technology or product makes itself an attractive target for acquisition.  See below for extrat from page 150 of the prospectus: As new devices gain regulatory approval, other treatments that were used to treat PAD may be replaced with the new devices. This is expected with DCBs and DEBs and the current stent market. As DCBs become available, the number of stents and stent procedures required will likely decline, and the number of balloon catheters used will gain market share in this device area.  The Company&rsquo s balloon catheters compete in this intense market against the larger incumbents such as Boston Scientific, CR Bard, and Abbott Laboratories. All of these large competitors use the same POBA technology. This means that there is minimal differentiation between products and the success rate of these products is limited by a high incidence of dissections. The use of stents (both BMS and DES) in the peripheral arteries has not produced the same clinical benefits as stents have produced when used in coronary arteries. In fact, many physicians try to avoid the use of a stent in the treatment of peripheral disease. As such, DCBs offer an attractive treatment alternative for patients with PV disease.  Medtronic aims to be the first to market in the US with its DCB device, IN.PACT, which was approved in Europe in 2008. Medtronic is estimating launch in the US of its product in the second half of 2015(1). However, competition is fierce as CR Bard recently released an announcement that they expect to file the final module for their pre-market approval (&ldquo PMA&rdquo ) application with the FDA in the fourth quarter of 2013, as the Lutonix DCB trial met its twelve (12)-month endpoints(2). CR Bard bought Lutonix in December 2011 for US$325 million(3). Other companies have also made inroads into this market through large acquisitions. For example, Covidien acquired CV Ingenuity, the makers of another DCB, in January 2013 and is targeting 2017 for FDA approval and Medtronic acquired Invatec in 2010 On the product pipeline, the company has an interesting lineup.  The next product that will be available for sale in the USA market would be its Chocolate PTCA which is awaiting for FDA approval.  Its next exciting product is the Drug Coated Chocolate, which is at stage 2 of its 3-stage development process with a targeted date for submission for CE mark in 2014, the success of this product/technology would be a game changer for the company. In summary, investors buying into the stock now are buying a company that has successfully developed various products approved by regulators and are being sold to hospitals and use by patients with good results a company that has its products distributed by strategic and premier international distributors in key markets,  and a company with good product pipeline.  Of course, the company still has a long way to go.  It needs to show the commercial potential of its products and its ability to execute and deliver all the expectations.
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 14:07        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Part 2 Sheerluck is correct to point out certain facts.  Working capital needs to be high to pay for salaries, stocking up of inventories for ramp up in sales volume, and etc.  As for bonus for CEO, it is a fixed sum of US$100k on achievement of performance target.  No profit sharing for directors, exe officers and employees. Of all the investors listed in page 75 of the prospectus, the only group that has invested less than 12 months with QTV before the IPO is the individual pre-IPO investors.  The rest of the sharholders Three Arch Partners, Luminor, BMSIF (EDB Investment), Adams Street have been shareholders of the company as early as 2007 and invested in few round of fundings up to Nov 2012.  While no one knows what these investors would do after the moratorium period is over, a logical guess for the fund investors is that they would likely monitor the company' s performance in terms of sales and new product pipelines and not simply because the moratorium period expires. I shall also present some further info here (pg 140 of prospectus). We have generated positive clinical data and we believe that our products offer compelling solutions for the treatment of complex vascular diseases.  While the cardiology and peripheral intervention markets are generally competitive, our Directors believe that there are no ideal solutions currently for opening blockages in the lower extremities, mainly the legs. Our Chocolate PTA reduces the strain and trauma induced on the vessel walls during inflation through the use of modules. In turn, this reduces the risk of complications as compared with conventional balloons and stents. Additionally, unlike stents, our Chocolate PTA is not a permanent implant and therefore avoids some of the long term complications associated with stents. During a human trial study of the Chocolate PTA on 22 patients in Germany and New Zealand for one (1) year, the Chocolate PTA achieved a 0% failure rate and subsequent follow-ups on these patients showed no complications. Additionally, data(1) from the first 350 patients of a separate human trial study of the Chocolate PTA in the United States showed that the use of Chocolate PTA was associated with high rates of treatment success and limb preservation and very low rates of dissections and bail-out stenting for patients with PAD. The study included a broad range of patients with advanced disease in their legs. As such, we believe that our Chocolate PTA provides a safe and effective solution for patients suffering from blockages in the legs. Our Directors also believe that our Chocolate PTA is the first of its kind produced in Singapore to be approved by the FDA and HSA.
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 14:05        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	Part 1 Just to share what I found out, given not all have the chance to meet the management. Use of proceeds of S$5mil for commercial expansion.  Is this enough?  Pg 124 of the prospectus states the change in the sales, marketing and distribution strategy.  In the past the company do direct sales to hospitals and physicians in USA, and collaborated with local distribution partners who assists to get regulatory approval outside USA.  With the distribution agreement with J& J, Weigao and Century Medical ( a unit of Itochu Japan), the company has changed its sales, marketing and distribution strategy.      It now partners J& J to distribute and sell its products in the USA and for markets outside the USA, the distribution strategy has shifted to utilising 3 main distribution partners, namely J& J, Weigao and Century Medical to sell, market and distribute.  Pg 125 of the prospectus provides the details pertaining to the exclusive distribution agreement with Cordis of Johnson & Johnson for its (1) peripheral products (excluding paclitaxel coated chocolate) in the USA, (2) peripheral and coronary products worldwide outside USA except Japan and China and (3) coronary products, paclitaxel coated chocolate and drug-coated chocolate PTCA in PRC.  The distribution agreement is for a period of 4 years and it also stipulates the minimum commitment of Cordis for each product for the first 2 years.  This means that the company can afford to spend less on marketing activities as Johnson & Johnson now takes on the marketing roles.  The sales force of J& J is understood to be 10 times larger than that of QTV.  Pg 125 also provides details on the distribution agreement with Weigao and Century Medical, which state that marketing expense are covered by the distributors.  I guess that all the above in a way explain the lower marketing expanses needed. Pg 95 of the prospectus explains the drop in the 9mFY2013 R& D expenses is due to the capitalization of the development expenses, ie addition to intellectual property.  Pg 91 of the prospectus states that R& D expense was US$4.8m, US$7.4m, US$6.9m, US$4.7m and and US$4.8 mil in FY2010, FY2011, FY2012, 9m2012 and 9m2013.  Thus, R& D was not compromised due to marketing. 9m2013 sales of US$3m vs 9m2012 sales of US$1.07 shows good growth momentum, whereas page 94 of the prospectus explained the drop in revenue in FY2012 vs FY2011 was due to the termination of an exclusive distribution agreement with IDEV Technologies for the distribution of GliderFlex PTA products.
Useful To Me  Not Useful To Me
cleverboy Member	05-May-2014 14:02        cleverboy About Contact  Quote this Post!
x 0   x 0  Alert Admin	test
Useful To Me  Not Useful To Me

                                                         First   < Newer   2321-2340 of 2353   Older>   Last